Curidium Medica

Curidium Medica was a UK-based personalized medicine company focused on the identification of targeted medicines and companion diagnostics for central nervous system (CNS) disorders. The company utilized its proprietary Homomatrix platform, a pattern recognition and mathematical algorithm tool, to analyze gene expression data and identify distinct patient subgroups within heterogeneous populations like schizophrenia and bipolar disorder. By classifying patients based on biological markers rather than just clinical symptoms, Curidium aimed to improve treatment efficacy and rescue failed drug candidates. The company was listed on the London Stock Exchange (AIM) before being acquired by Avacta Group in 2009 to bolster its diagnostics portfolio. Its technology was designed to de-risk drug discovery by identifying patient subgroups most likely to respond to specific therapies.